Viewing nowCombinationSitafomin Alpha Tablets 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daehan New Pharm Co., Ltd.

MFDS item code 202200111 · Approved 2022.01.06 · Insurance code 669908230
Improvement of blood glucose control in patients with type 2 diabetes mellitus
This medication is an adjunct used to help control blood sugar in patients with type 2 diabetes, alongside diet and exercise therapy. It is particularly effective in patients who have not previously received diabetes medication and find it difficult to control blood sugar with monotherapy. It can also be used when sufficient effect is not achieved with monotherapy of Metformin or Sitagliptin, or when replacing combinations of the two medications. If blood sugar control is difficult, it can be administered in combination with other treatments such as sulfonylureas, thiazolidinediones, or insulin. This helps improve blood sugar control when used with various treatment methods.
The dose of this product for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This product is generally taken 2 times daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this product should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this product is 1 tablet of 50/500 mg 2 times daily. The dose may be increased to 1 tablet of 50/1000 mg 2 times daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this product (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this product is sitagliptin 50 mg 2 times daily (total daily dose of 100 mg) and the patient's existing metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this product may start at their existing doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with concomitant metformin and sulfonylurea therapy, metformin and insulin therapy, or metformin and thiazolidinedione therapy: The initial dose of this product is sitagliptin 50 mg 2 times daily (total daily dose of 100 mg). The initial dose of metformin should be determined based on the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When this product is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment This product may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this product, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg 2 times daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this product should be discontinued immediately.
This medication contains Sitagliptin and Metformin as diabetes treatments and has several important precautions for use. First, there may be serious allergic reactions during the use of this medication, so if symptoms such as skin rash or breathing difficulties occur, you should immediately stop taking it and consult a doctor. Second, acute pancreatitis may occur, so if abdominal pain, nausea, or vomiting persists, seek medical attention immediately. Third, patients with impaired kidney function, dehydration, severe infections, or heart failure should not take this medication, and regular kidney function tests should be conducted before and during treatment. Fourth, it is safer for women who are pregnant or may become pregnant, as well as nursing mothers, not to use this medication. Fifth, hypoglycemia may occur while taking this medication, so caution is especially needed when taken with other blood sugar-lowering drugs, and immediate action should be taken if symptoms arise. Sixth, Metformin can rarely cause serious metabolic abnormality called lactic acidosis. If there is acute kidney impairment, dehydration, severe infection, or liver dysfunction, the medication should be discontinued, and symptoms such as muscle pain, breathing difficulty, or weakness require attention. Seventh, regular blood tests and kidney function tests should be conducted during treatment, and vitamin B12 deficiency may occur, so supplementation should be given if necessary. Finally, alcohol consumption may increase the risk of lactic acidosis, so you should avoid excessive drinking while taking this medication, and it may be necessary to stop taking it for a certain period before and after surgery. By adhering to these precautions and following your doctor's instructions, one can safely benefit from the therapeutic effects of this medication.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly closed container to prevent exposure to air and moisture, and it is recommended to keep it at room temperature between 1 and 30 degrees Celsius.
Pink oval film-coated tablets
30 tablets/box [10 tablets/PTP x 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daehan New Pharm Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.